Published in J Neuroimmunol on July 15, 2010
Remyelination therapy for multiple sclerosis. Neurotherapeutics (2013) 1.08
Regulation of human glia by multiple sclerosis disease modifying therapies. Semin Immunopathol (2015) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol (1980) 5.63
Debris clearance by microglia: an essential link between degeneration and regeneration. Brain (2008) 3.36
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med (1999) 3.13
Multiple extracellular signals are required for long-term oligodendrocyte survival. Development (1993) 2.55
Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci (1998) 2.17
IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol (2004) 2.02
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain (2002) 2.02
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron (1993) 1.93
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia (2001) 1.71
Endothelin-1 regulates astrocyte proliferation and reactive gliosis via a JNK/c-Jun signaling pathway. J Neurosci (2008) 1.60
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med (2002) 1.57
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53
Glatiramer acetate: evidence for a dual mechanism of action. J Neurol (2008) 1.49
Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci U S A (2009) 1.46
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A (2005) 1.44
Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci (2000) 1.44
Remyelination in multiple sclerosis. J Neurol Sci (2003) 1.43
Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. J Virol (2001) 1.42
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol (1998) 1.38
Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci (2006) 1.35
Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol (2004) 1.34
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 1.33
Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol (1998) 1.33
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain (2004) 1.32
Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia (2006) 1.28
Neuro-immune crosstalk in CNS diseases. Neuroscience (2008) 1.22
Inflammation stimulates remyelination in areas of chronic demyelination. Brain (2005) 1.21
Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A (2004) 1.17
The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. J Neurosci (1998) 1.13
Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 1.11
Elevated levels of the chemokine GRO-1 correlate with elevated oligodendrocyte progenitor proliferation in the jimpy mutant. J Neurosci (2000) 1.10
Patterning of spinal cord oligodendrocyte development by dorsally derived BMP4. J Neurosci Res (2004) 1.07
Mechanisms of immunomodulation by glatiramer acetate. Neurology (2000) 1.04
Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A (2009) 1.02
NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo. J Neurosci Res (1998) 1.02
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics (2007) 1.01
Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci (2003) 1.00
Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol (1999) 0.99
Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. Glia (2003) 0.96
Microglia-derived IGF-2 prevents TNFalpha induced death of mature oligodendrocytes in vitro. J Neuroimmunol (2002) 0.93
CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol (2007) 0.91
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol (2003) 0.89
Telomerase and oligodendrocyte differentiation. J Neurobiol (2001) 0.88
The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol (2006) 0.88
NT-3 weakly stimulates proliferation of adult rat O1(-)O4(+) oligodendrocyte-lineage cells and increases oligodendrocyte myelination in vitro. J Neurosci Res (2000) 0.86
Intrinsic and extrinsic inhibition of oligodendrocyte development by rat retina. Dev Biol (2006) 0.86
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci (2002) 0.81
Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes. Cell Res (2009) 0.80
Mitotic potential of adult rat oligodendrocytes in culture. J Neurosci Res (1992) 0.78
Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin Immunol (2004) 0.77
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn (1992) 3.14
Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler (2011) 2.77
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology (2010) 2.30
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07
Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease. Neurol Sci (2014) 1.97
Airbag-associated ocular injury and periorbital fractures. Arch Ophthalmol (1993) 1.92
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem (2000) 1.79
Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem (2000) 1.76
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 1.71
Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia (2000) 1.70
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Incidence of acquired demyelination of the CNS in Canadian children. Neurology (2009) 1.63
The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol (2001) 1.56
Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. Ann Neurol (1991) 1.54
Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med (1996) 1.53
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol (1996) 1.51
Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg (1990) 1.46
Neuroleukin: a lymphokine product of lectin-stimulated T cells. Science (1986) 1.44
PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res (1997) 1.43
Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology (1992) 1.42
Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology (2000) 1.42
Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy. Mayo Clin Proc (1991) 1.37
Glial cell influence on the human blood-brain barrier. Glia (2001) 1.36
Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia (1996) 1.35
Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1beta in primary human fetal astrocytes. J Neurosci (2000) 1.33
Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol (1997) 1.27
Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc Natl Acad Sci U S A (1991) 1.27
MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol (1998) 1.26
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology (2011) 1.25
Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain (2000) 1.25
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol (1992) 1.24
Inhibition of terminal axonal sprouting by serum from patients with amyotrophic lateral sclerosis. N Engl J Med (1984) 1.23
Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J Neuropathol Exp Neurol (2001) 1.20
The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem (1997) 1.20
Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol (2010) 1.20
Biology of adult human microglia in culture: comparisons with peripheral blood monocytes and astrocytes. J Neuropathol Exp Neurol (1992) 1.19
Impact of sleep disorder treatment on fatigue in multiple sclerosis. Mult Scler (2012) 1.18
Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology (1994) 1.18
Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol (1979) 1.17
In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain (1999) 1.17
Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia (2007) 1.16
Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol (1997) 1.15
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler (2008) 1.13
Circulating suppressor cells in man as a function of age. Clin Immunol Immunopathol (1978) 1.13
Amyotrophic lateral sclerosis with antecedent poliomyelitis. Arch Neurol (1980) 1.13
Bilateral juxtapapillary subretinal neovascularization associated with pseudotumor cerebri. Am J Ophthalmol (1981) 1.12
HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology (2011) 1.11
Regulation of CD14 expression on human adult central nervous system-derived microglia. J Neurosci Res (1996) 1.11
Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination. Neurology (2011) 1.10
Inhibition of medulloblastoma cell invasion by Slit. Oncogene (2006) 1.09
Changes in concanavalin A capping of human lymphocytes with age. Mech Ageing Dev (1980) 1.09
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Soluble CD14(1-152) confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay. J Immunol (1998) 1.06
Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. Mult Scler (2007) 1.06
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology (2011) 1.05
Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol (1995) 1.04
A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol (1995) 1.04
B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol (1994) 1.03
Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest (1996) 1.02
IL-10 production by adult human derived microglial cells. Neurochem Int (1996) 1.02
Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol (1994) 1.01
Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neurol (1996) 1.00
Linkage analysis in familial amyotrophic lateral sclerosis. Neurology (1989) 1.00
Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol (1983) 1.00
CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS. J Neuroimmunol (2000) 0.98
Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci (1995) 0.98
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology (2009) 0.98
Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery (1991) 0.97
Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol (2000) 0.96
Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat Med (2000) 0.96
Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology (2000) 0.95
Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis. Ann Neurol (1982) 0.94
Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol (2000) 0.93
Eye injury: prevalence and prognosis by setting. South Med J (1989) 0.93
Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol (1999) 0.93
p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF. J Neurosci (1998) 0.93
T cell regulation of polyclonally induced immunoglobulin secretion in humans. J Immunol (1984) 0.93
Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol (1999) 0.92
NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol (2001) 0.92
Susceptibility of astrocytes to class I MHC antigen-specific cytotoxicity. J Immunol (1987) 0.92
Immunohistochemical studies of adult human glial cells. J Neuroimmunol (1989) 0.92
Experimental models of neuroprotection relevant to multiple sclerosis. Neurology (2007) 0.91
Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol (1986) 0.91
Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery (1992) 0.90
Activation of adult human derived microglia by myelin phagocytosis in vitro. J Neurosci Res (1994) 0.89
Motor neuron disease: decremental responses to repetitive nerve stimulation. Neurology (1981) 0.89
Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology (1979) 0.89
Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol (1999) 0.89
Reduced T-lymphocyte cell reactivity as a function of human aging. Cell Immunol (1980) 0.89